Sökning: WFRF:(HOLMBERG E) >
A randomised study ...
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi,Uppsala University Hospital
-
- Andersson, M. (författare)
- Copenhagen University Hospital,Rigshosp, Dept Oncol, Copenhagen, Denmark
-
- Ahlgren, J. (författare)
- Gävle Hospital,Gavle Cent Hosp, Dept Oncol, Gavle, Sweden;Orebro Univ Hosp, Dept Oncol, Orebro, Sweden,Aarhus Univ Hosp, Dept Oncol, Aarhus, Denmark,Aarhus University Hospital
-
visa fler...
-
- Balslev, E. (författare)
- Herlev Hospital,Herlev Hosp, Dept Oncol, Herlev, Denmark,Rigshosp, Dept Oncol, Copenhagen, Denmark,Copenhagen University Hospital
-
- Sverrisdottir, A. (författare)
- Stockholm South General Hospital,Soder Sjukhuset, Dept Oncol, Stockholm, Sweden;Landspitali, Dept Oncol, Reykjavik, Iceland
-
- Holmberg, S. B. (författare)
- Sahlgrenska University Hospital,Dept Surg, Molndal, Sweden
-
- Bengtsson, N. O. (författare)
- Umeå University,Umea Univ Hosp, Dept Oncol, Umea, Sweden
-
- Jacobsen, E. H. (författare)
- Vejle Hospital,Vejle Hosp, Dept Oncol, Vejle, Denmark,Vasteras Hosp, Dept Oncol, Vasteras, Sweden;Aalborg Univ Hosp, Dept Oncol, Aalborg, Denmark,Västmanland Hospital
-
- Jensen, A. B. (författare)
- Karolinska Institute,Karolinska Institutet,Karolinska University Hospital
-
- Hansen, J. (författare)
- Västmanland Hospital
-
- Tuxen, M. K. (författare)
- Herlev Hospital,Herlev Hosp, Dept Oncol, Herlev, Denmark
-
- Malmberg, L. (författare)
- Karlstad Hospital,Karlstad Hosp, Dept Oncol, Karlstad, Sweden;Boras Hosp, Dept Oncol, Boras, Sweden
-
- Villman, K. (författare)
- Örebro University Hospital,Orebro Univ Hosp, Dept Oncol, Orebro, Sweden
-
- Anderson, H. (författare)
- Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Dept Clin Sci, Div Canc Epidemiol, Lund, Sweden
-
- Ejlertsen, B. (författare)
- Copenhagen University Hospital
-
- Bergh, J. (författare)
- Karolinska Institute,Karolinska University Hospital
-
- Blomqvist, C. (författare)
- Uppsala universitet,Institutionen för immunologi, genetik och patologi,Orebro Univ Hosp, Dept Oncol, Orebro, Sweden,Uppsala University Hospital
-
visa färre...
-
(creator_code:org_t)
-
-
visa fler...
-
-
-
visa färre...
- Elsevier BV, 2018
- 2018
- Engelska 8 s.
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049 .- 1879-0852. ; 94, s. 79-86
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Study aim: Retrospective studies have demonstrated a worse outcome in breast cancer patients not developing leukopenia during adjuvant chemotherapy. The SBG 2000-1 is the first randomised trial designed to compare individually dosed chemotherapy without G-CSF support based on grade of toxicity to standard-dosed chemotherapy based on body surface area (BSA). Methods: Patients with early breast cancer were included and received the first cycle of standard FEC (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2). Patients with nadir leukopenia grade 0–2 after first cycle were randomised between either 6 additional courses of tailored FEC with increased doses (E 75–90 mg/m2, C 900–1200 mg/m2) or fixed treatment with 6 standard FEC. Patients with grade 3–4 leukopenia were registered and treated with 6 standard FEC. Primary end-point was distant disease-free survival (DDFS). Results: The study enrolled 1535 patients, of which 1052 patients were randomised to tailored FEC (N = 524) or standard FEC (N = 528), whereas 401 patients with leukopenia grade 3–4 continued standard FEC and formed the registered cohort. Dose escalation did not statistically significantly improve 10-year DDFS (79% and 77%, HR 0.87, CI 0.67–1.14, P = 0.32) or OS (82% and 78%, respectively, HR 0.89, CI 0.57–1.16, P = 0.38). Corresponding estimates for the registered group of patients were DDFS 79% and OS 82%, respectively. Conclusions: The SBG 2000-1 study failed to show a statistically significant improvement of escalated and tailored-dosed chemotherapy compared with standard BSA-based chemotherapy in patients with low haematological toxicity, although all efficacy parameters showed a numerical advantage for tailored treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Adjuvant
- Breast cancer
- Chemotherapy
- Dosage
- Dose tailoring
- Leukopenia
- Adjuvant
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lindman, Henrik
-
Andersson, M.
-
Ahlgren, J.
-
Balslev, E.
-
Sverrisdottir, A ...
-
Holmberg, S. B.
-
visa fler...
-
Bengtsson, N. O.
-
Jacobsen, E. H.
-
Jensen, A. B.
-
Hansen, J.
-
Tuxen, M. K.
-
Malmberg, L.
-
Villman, K.
-
Anderson, H.
-
Ejlertsen, B.
-
Bergh, J.
-
Blomqvist, C.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Lunds universitet
-
Uppsala universitet
-
Karolinska Institutet